Dyslipidemia Clinical Trial
| NCT number | NCT02480816 |
| Other study ID # | BW-13 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | May 1, 2015 |
| Est. completion date | February 1, 2016 |
| Verified date | September 2018 |
| Source | National Research Council, Spain |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The effects of consuming a sodium-bicarbonated mineral water rich in bicarbonate, sodium, chloride, lithium and silicon are studied in humans. The aim of this assay was to determine whether the consumption of this water as part of the usual diet, reduces cardiometabolic risk factors in adult men and women.
| Status | Completed |
| Enrollment | 72 |
| Est. completion date | February 1, 2016 |
| Est. primary completion date | November 1, 2015 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 45 Years |
| Eligibility |
Inclusion Criteria: - Healthy adults, men and women >18 and = 45 years - Total-cholesterol > 200 mg/dL and < 300 mg/dL Exclusion Criteria: - Age <18 and > 45 years - Total-cholesterol =300 mg/dL - Triglycerides > 250 mg/dL - Total-cholesterol / HDL-cholesterol > 6 - Being a usual consumer of carbonic mineral water - BMI < 20 and >30 kg/m2 - Diabetes - Hypertension or digestive, liver or renal disease - Eating disorders - Being under medication that could affect lipid metabolism - Consumption of functional foods that could affect lipid metabolism (food containing n-3 fatty acids or phytosterols) |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| National Research Council, Spain |
Toxqui L, Vaquero MP. An Intervention with Mineral Water Decreases Cardiometabolic Risk Biomarkers. A Crossover, Randomised, Controlled Trial with Two Mineral Waters in Moderately Hypercholesterolaemic Adults. Nutrients. 2016 Jun 28;8(7). pii: E400. doi: — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | LDL-cholesterol | Baseline | ||
| Primary | LDL-cholesterol | 4 weeks | ||
| Primary | LDL-cholesterol | 8 weeks | ||
| Secondary | Total-cholesterol | Baseline | ||
| Secondary | Total-cholesterol | 4 weeks | ||
| Secondary | Total-cholesterol | 8 weeks | ||
| Secondary | Triglycerides | Baseline | ||
| Secondary | Triglycerides | 4 weeks | ||
| Secondary | Triglycerides | 8 weeks | ||
| Secondary | HDL-cholesterol | Baseline | ||
| Secondary | HDL-cholesterol | 4 weeks | ||
| Secondary | HDL-cholesterol | 8 weeks | ||
| Secondary | Apolipoprotein A | Baseline | ||
| Secondary | Apolipoprotein A | 4 weeks | ||
| Secondary | Apolipoprotein A | 8 weeks | ||
| Secondary | Apolipoprotein B | Baseline | ||
| Secondary | Apolipoprotein B | 4 weeks | ||
| Secondary | Apolipoprotein B | 8 weeks | ||
| Secondary | Glucose | Baseline | ||
| Secondary | Glucose | 4 weeks | ||
| Secondary | Glucose | 8 weeks | ||
| Secondary | Insulin | Baseline | ||
| Secondary | Insulin | 4 weeks | ||
| Secondary | Insulin | 8 weeks | ||
| Secondary | Urine creatinin | Baseline | ||
| Secondary | Urine creatinin | 8 weeks | ||
| Secondary | Urine calcium | Baseline | ||
| Secondary | Urine calcium | 8 weeks | ||
| Secondary | Urine potassium | Baseline | ||
| Secondary | Urine potassium | 8 weeks | ||
| Secondary | Urine sodium | Baseline | ||
| Secondary | Urine sodium | 8 weeks | ||
| Secondary | Urine pH | Baseline | ||
| Secondary | Urine pH | 8 weeks | ||
| Secondary | Systolic Blood Pressure | Baseline | ||
| Secondary | Systolic Blood Pressure | 4 weeks | ||
| Secondary | Systolic Blood Pressure | 8 weeks | ||
| Secondary | Diastolic Blood Pressure | Baseline | ||
| Secondary | Diastolic Blood Pressure | 4 weeks | ||
| Secondary | Diastolic Blood Pressure | 8 weeks | ||
| Secondary | Oxidized LDL | Baseline | ||
| Secondary | Oxidized LDL | 4 weeks | ||
| Secondary | Oxidized LDL | 8 weeks | ||
| Secondary | Serum aldosterone | Baseline | ||
| Secondary | Serum aldosterone | 8 weeks | ||
| Secondary | BMI | Baseline | ||
| Secondary | BMI | 4 weeks | ||
| Secondary | BMI | 8 weeks | ||
| Secondary | Dietary energy intake | Baseline | ||
| Secondary | Dietary energy intake | 8 weeks | ||
| Secondary | Dietary protein intake | Baseline | ||
| Secondary | Dietary protein intake | 8 weeks | ||
| Secondary | Dietary fat intake | Baseline | ||
| Secondary | Dietary fat intake | 8 weeks | ||
| Secondary | Dietary cholesterol intake | Baseline | ||
| Secondary | Dietary cholesterol intake | 8 weeks | ||
| Secondary | Dietary carbohydrate intake | Baseline | ||
| Secondary | Dietary carbohydrate intake | 8 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
| Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
| Recruiting |
NCT02837367 -
Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People
|
N/A | |
| Active, not recruiting |
NCT02600338 -
Meta-analyses of the Effect of Legumes on Blood Pressure
|
N/A | |
| Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
| Completed |
NCT02163044 -
The Hellenic Postprandial Lipemia Study (HPLS)
|
||
| Recruiting |
NCT01972113 -
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
|
N/A | |
| Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
| Completed |
NCT01764295 -
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
|
Phase 3 | |
| Completed |
NCT01531062 -
Effect of Nigella Sativa on Lipid Profiles in Elderly
|
Phase 2 | |
| Completed |
NCT01990391 -
Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities
|
N/A | |
| Terminated |
NCT01414166 -
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
|
Phase 3 | |
| Recruiting |
NCT01670968 -
HIV Reverse Cholesterol Transport Study
|
||
| Completed |
NCT00977288 -
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
|
Phase 2 | |
| Withdrawn |
NCT00664287 -
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
|
Phase 3 | |
| Completed |
NCT00768274 -
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
|
Phase 1/Phase 2 | |
| Completed |
NCT01285544 -
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
|
Phase 4 | |
| Completed |
NCT00300430 -
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
|
Phase 3 | |
| Completed |
NCT01483235 -
Reduced Cardiac Rehabilitation Program
|
N/A | |
| Completed |
NCT00309738 -
Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
|
Phase 3 |